Successfully Printing 109% Profit Growth in 2025, Phapros (PEHA) Distributes 15% Dividend

JAKARTA, June 11, 2026 – PT Phapros Tbk ("PEHA"), a leading pharmaceutical company in Indonesia, has successfully held its Annual General Meeting of Shareholders (AGMS) in Jakarta, Thursday, June 11, 2026.

The Phapros Annual AGMS discussed five main agendas, including:

1. Approval of the Company's Annual Report and ratification of the company's consolidated financial statements for the 2025 Financial Year
2. Approval of the use of the company's net profit
3. Determination of salary/honorarium, facilities, and allowances for the 2026 Financial Year
4. Appointment of a public accountant
5. Material transactions.

In the Phapros Annual AGMS, the shareholders have approved all the agendas proposed by the company, including the agenda item on the use of the company's net profit for the 2025 Financial Year, namely the distribution of cash dividends to shareholders amounting to 15% of the Company's net profit, and the remainder will be used as a reserve fund for CAPEX to fulfill the Company's compliance.

During the Annual AGMS presentation, Intan Abdams Katoppo, President Director of PT Phapros Tbk, presented the Phapros Annual Financial Report for the 2025 Financial Year; on this occasion, she conveyed that the Company had successfully achieved an excellent performance in 2025 with significant growth in sales and net profit. Therefore, according to her, the Company agreed to distribute dividends to shareholders. Intan emphasized that this decision is a manifestation of the company's appreciation for the loyalty of PEHA investors and demonstrates a stable financial condition and positive cash flow.

"Phapros is committed to continuing to provide added value to shareholders, including through the distribution of dividends. This reflects Phapros' solid and healthy financial performance and strong business fundamentals. The company is on the right track to maintain profitability sustainability. Therefore, we are optimistic that the company will again provide added value to shareholders in the following years," said Intan during the Phapros Public Expose in Jakarta, Thursday (June 11, 2026).

Phapros successfully recorded a net profit in 2025 of Rp27.4 billion, growing 109%, compared to 2024 which experienced a loss of Rp290.6 billion. PEHA's profit was driven by double-digit sales growth and the success of its operational efficiency strategy. As seen in the Company's published Audited Financial Statements, Phapros' sales in 2025 amounted to Rp940.88 billion, an increase of 26.34% annually (year-on-year/y-o-y). The increase in sales occurred across all product segments. The over-the-counter (OTC) drug segment rose 43.20% y-o-y, the branded generic drug (OGB) segment grew 13.95% y-o-y, and the ethical segment soared by 55% y-o-y.

In addition, throughout 2025, the company was also able to reduce production costs or the cost of goods sold (COGS) by 5.41% to Rp448.37 billion compared to the previous year's Rp474.03 billion. This excellent performance was further strengthened by the company's ability to reduce operating expenses, which were successfully lowered by 14.64% to Rp406.43 billion in 2025 compared to Rp476.12 billion in 2024.

Cost Restructuring

Intan explained that the cost restructuring strategy throughout 2025 proved successful in carrying out production efficiency. This can be seen from the 5.41% decrease in COGS. The ratio of COGS to sales in 2025 also dropped significantly to 47.65% compared to 2024's 63.65%. The low ratio of COGS to sales indicates that the production process is running very efficiently with a larger gross profit margin.

Another positive achievement is the successful reduction of liabilities in 2025 to Rp959.70 billion, down 7.45% (y-o-y) compared to Rp1,036.92 billion in 2024. The success in cutting liabilities has driven an increase in equity in 2025 to Rp427.47 billion, an increase of 8.74% compared to the previous year's Rp393.12 billion. This equity growth also indicates that the company is becoming more valuable to owners/shareholders. Not only profit, but Phapros was also able to maintain its cash flow well. Net cash flow from the company's operating activities was positive at Rp123.757 billion, with a cash balance as of December 31, 2025, of Rp120.98 billion, up 31.49% compared to the same period the previous year of Rp92 billion.

"The positive parameters that have been carved out throughout the 2025 financial year are a new spirit for Management to prove that Phapros can continue to grow and meet the expectations of shareholders sustainably. Phapros definitely can, Phapros is healthy, Healthy is Phapros," concluded Intan.